1
|
Samlowski W. The Effect of Non-Overlapping Somatic Mutations in BRAF, NRAS, NF1, or CKIT on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma. Cancers (Basel) 2024; 16:594. [PMID: 38339344 PMCID: PMC10854687 DOI: 10.3390/cancers16030594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 01/24/2024] [Accepted: 01/29/2024] [Indexed: 02/12/2024] Open
Abstract
Previous studies suggested that somatic BRAF and NRAS mutations in metastatic melanoma increase the risk for brain metastases. The risk related to other non-overlapping "driver" mutations is unknown. We performed a retrospective evaluation of the incidence, timing, and outcome of brain metastases in a population of melanoma patients that underwent uniform next-gen sequencing. All patients were treated with initial checkpoint inhibitor therapy. Seventeen of 88 patients (20.0%) developed brain metastases. Eleven patients had brain metastases at diagnosis (12.9%). These were all patients with BRAF V600 or NF1 mutations. Only six patients with NRAS, NF1, KIT, or BRAF mutations (including fusions/internal rearrangements experienced delayed CNS progression following immunotherapy (7.1%)). No "quadruple negative" patient developed brain metastases. Patients with brain metastases at diagnosis had a better outcome than those with delayed intracranial progression. Current predictive markers, (LDH, tumor mutation burden, and PDL1) were poorly correlated with the development of brain metastases. Treatment with immunotherapy appears to reduce the incidence of brain metastases. Next-gen molecular sequencing of tumors in metastatic melanoma patients was useful in identifying genetic subpopulations with an increased or reduced risk of brain metastases. This may allow eventual personalization of screening strategies.
Collapse
Affiliation(s)
- Wolfram Samlowski
- Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA; ; Tel.: +1-702-321-3930
- Kirk Kerkorian School of Medicine, University of Nevada Las Vegas (UNLV), Las Vegas, NV 89106, USA
- School of Medicine, University of Nevada (Reno), Reno, NV 89557, USA
| |
Collapse
|
2
|
Patel SP, Othus M, Chae YK, Dennis MJ, Gordon S, Mutch D, Samlowski W, Robinson WR“R, Sharon E, Ryan C, Lopez G, Plets M, Blanke C, Kurzrock R. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia. Clin Cancer Res 2024; 30:33-38. [PMID: 37882676 PMCID: PMC10842092 DOI: 10.1158/1078-0432.ccr-23-2293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 08/28/2023] [Accepted: 10/24/2023] [Indexed: 10/27/2023]
Abstract
PURPOSE The efficacy of immune checkpoint blockade in gestational trophoblastic neoplasia (GTN) remains uncertain. We report the results of the GTN cohort of SWOG S1609 dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). PATIENTS AND METHODS This prospective, open-label phase II trial evaluated ipilimumab plus nivolumab across multiple rare tumor cohorts, including GTN. Eligible patients received nivolumab 240 mg, i.v. every 2 weeks and ipilimumab 1 mg/kg i.v. every 6 weeks. The primary endpoint was overall response rate [ORR; complete response (CR) + partial response (PR)] by quantitative serum beta human chorionic gonadotropin (β-hCG); secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity. RESULTS Four patients with refractory GTN enrolled and received therapy. At 11 months of ongoing follow-up, 3 of 4 patients responded [ORR = 75% (CR, 25%, n = 1, tumor mutation burden = 1 mutation/megabase; PD-L1 tumor proportion score = 50%); PR, 50%, n = 2)]. Responders included malignant gestational trophoblastic neoplasm (n = 1, CR, PFS 11+ months) and choriocarcinoma (n = 2, both PRs, PFS 10+ and 6+ months). One patient with epithelioid trophoblastic tumor experienced disease progression. The 6-month PFS was 75% [95% confidence interval (CI), 43%-100%], and the median PFS was not reached (range, 35-339+ days); all 4 patients were alive at last follow-up. Two patients experienced grade 3 immune-related toxicity (arthralgia and colitis); there were no grade ≥4 events. CONCLUSIONS Ipilimumab plus nivolumab demonstrated efficacy in chemotherapy-refractory GTN, an ultra-rare cancer affecting young women. Three of 4 patients achieved ongoing objective responses with a reasonable safety profile at 6-11+ months.
Collapse
Affiliation(s)
- Sandip P. Patel
- Division of Medical Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA, USA
| | - Megan Othus
- SWOG Statistical and Data Management Center/Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA
| | - Young Kwang Chae
- Division of Medical Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Michael J. Dennis
- Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Sarah Gordon
- Virginia Commonwealth University/Massey Cancer Center Division of Hematology, Oncology, Palliative Care, Virginia Commonwealth University, Richmond, VA, USA (during conduct of trial); Thomas Jefferson University/Sidney Kimmel Cancer Center, Philadelphia, PA, USA (current affiliation)
| | - David Mutch
- Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA
| | - Wolfram Samlowski
- Division of Medical Oncology, Nevada Cancer Institute, Las Vegas, NV, USA
| | - William R. “Rusty” Robinson
- Division of Gynecologic Oncology, University of Mississippi Medical Center Cancer Center and Research Institute, Jackson, MS, USA (during conduct of trial); Tulane Medical School, New Orleans, LA, USA (current affiliation)
| | - Elad Sharon
- Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD, USA
| | - Christopher Ryan
- Division of Hematology and Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA
| | - Gabby Lopez
- SWOG Statistical and Data Management Center/Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA
| | - Melissa Plets
- SWOG Statistical and Data Management Center/Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA
| | - Charles Blanke
- SWOG Group Chair’s Office/Knight Cancer Institute, Oregon Health & Science University, Portland, OR
| | - Razelle Kurzrock
- Division of Medical Oncology, Medical College of Wisconsin Froedtert Cancer Center, Milwaukee, WI, USA
| |
Collapse
|
3
|
Wescott R, Samlowski W. Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series. Curr Oncol 2023; 30:9156-9167. [PMID: 37887561 PMCID: PMC10604938 DOI: 10.3390/curroncol30100661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Revised: 10/07/2023] [Accepted: 10/10/2023] [Indexed: 10/28/2023] Open
Abstract
Nevoid basal-cell carcinoma syndrome (Gorlin syndrome) is characterized by numerous cutaneous basal cell carcinomas mediated by mutations in the hedgehog pathway. Vismodegib or sonidegib represent promising treatment options. We identified 10 Gorlin patients who were treated with sonidegib (n = 6) or vismodegib (n = 4) between March 2012 and March 2022. We analyzed the activity, toxicity, and duration of the response to oral hedgehog inhibitors. The number of new tumors that developed prior to treatment or after treatment as well as the time of response and durability of responses were assessed. All patients achieved a complete remission. With a 30.7 ± 48.4-month median follow-up, the drug treatment significantly reduced the number of new basal cell cancers from a mean of 28.3 ± 24.6 prior to treatment to a mean of 1.4 ± 2.0 during treatment (p = 0.0048). The median time to develop a new basal cell cancer was 47.3 months. Three patients eventually developed localized recurrences. After resection, ongoing treatment suppressed the development of additional lesions. One patient developed numerous new drug-resistant basal cell cancers and died of acute leukemia. Six patients required treatment modifications for toxicity. Sustained hedgehog inhibitor treatment can suppress the progression of both new and existing basal cell carcinomas for an extended period. Drug administration schedule adjustments improved tolerance without altering efficacy, potentially contributing to a prolonged response duration.
Collapse
Affiliation(s)
- Raquel Wescott
- School of Medicine, University of Nevada, Reno, NV 89557, USA;
| | - Wolfram Samlowski
- School of Medicine, University of Nevada, Reno, NV 89557, USA;
- Comprehensive Cancer Centers of Nevada (Medical Oncology), Las Vegas, NV 89148, USA
- Department of Medicine, Kirk Kirkorian School of Medicine, University of Nevada Las Vegas (UNLV), Las Vegas, NV 89106, USA
| |
Collapse
|
4
|
Chang M, Samlowski W, Meoz R. Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series. Oncotarget 2023; 14:709-718. [PMID: 37417890 DOI: 10.18632/oncotarget.28470] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/08/2023] Open
Abstract
BACKGROUND Treatment for locally advanced cutaneous squamous cell cancers (laCSCC) remains poorly defined. Most laCSCC tumors express high levels of epidermal growth factor receptors (EGFR). Cetuximab has activity in other EGFR expressing cancers and enhances the effectiveness of radiotherapy. METHODS A retrospective review of institutional data identified eighteen patients with laCSCC treated with cetuximab induction and concurrent radiotherapy. The loading dose of cetuximab was 400 mg/m² IV. Subsequent weekly doses of 250 mg/m² IV were infused throughout the period of radiation. The treatment doses ranged from 4500-7000 cGy, with a dose fraction of 200-250 cGy. RESULTS The objective response rate was 83.2% with 55.5% complete responses and 27.7% partial responses. Median progression-free survival was 21.6 months. Progression-free survival was 61% at 1 year and 40% at 2 years. With longer follow-up, some patients developed a local recurrence (16.7%), distant metastases (11.1%) or a second primary cancer (16.3%). Cetuximab was well tolerated, with 68.4% patients experienced only mild acneiform skin rash or fatigue (Grade 1 or 2). Radiotherapy produced expected side effects (skin erythema, moist desquamation, mucositis). DISCUSSION Cetuximab plus radiotherapy represents an active and tolerable treatment option for laCSCC, including patients with contraindications for checkpoint inhibitor therapy.
Collapse
Affiliation(s)
- Mark Chang
- University Medical Center of Southern Nevada, Las Vegas, NV 89102, USA
| | - Wolfram Samlowski
- Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA
- Department of Internal Medicine, University of Nevada, Las Vegas (UNLV), Las Vegas, NV 89102, USA
- Department of Internal Medicine, University of Nevada, Reno, NV 89557, USA
| | - Raul Meoz
- Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA
- Department of Internal Medicine, University of Nevada, Las Vegas (UNLV), Las Vegas, NV 89102, USA
| |
Collapse
|
5
|
Panning A, Samlowski W, Allred G. Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma. Cancers (Basel) 2023; 15:3527. [PMID: 37444637 DOI: 10.3390/cancers15133527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2023] [Revised: 07/01/2023] [Accepted: 07/03/2023] [Indexed: 07/15/2023] Open
Abstract
BACKGROUND Non-overlapping somatic mutations in BRAF, NRAS, or NF1 genes occur in 85% of metastatic melanoma patients. It is not known whether these mutations affect immunotherapy outcome. MATERIALS AND METHODS Next-Gen sequencing of 324 oncogenes was performed in 73 metastatic melanoma patients. A retrospective review of immunotherapy outcome was performed. RESULTS BRAF fusions/internal rearrangements, BRAF V600E, NRAS, NF1 mutations, and triple-negative genotypes occurred in 6.9%, 30.1%, 17.8%, 32.9%, and 12.3% of patients, respectively. Median potential follow-up was 41.0 months. Patients with BRAF fusion/rearrangement had decreased progression-free and overall survival (p = 0.015). The other genotypes each had similar progression-free and overall survival. Patients who achieved a complete best objective response at 12 months (n = 36, 49.3%) were found to have significantly improved survival compared those who failed to achieve remissions (n = 37, 50.7%, p < 0.001). CONCLUSIONS The most important determinant of long-term survival was achievement of a complete response by 12 months following immunotherapy. PR and SD were not a stable type of response and generally resulted in progression and death from melanoma. Rare patients with BRAF fusions or rearrangements had decreased progression-free and overall survival following initial immunotherapy. Other BRAF, NRAS, or NF1 mutations were not associated with significant differences in outcome.
Collapse
Affiliation(s)
- Alyssa Panning
- Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89106, USA
| | - Wolfram Samlowski
- Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89106, USA
- Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA
- School of Medicine, University of Nevada, Reno, NV 89557, USA
| | - Gabriel Allred
- Gables Statistical Consulting, Bella Vista, AR 72714, USA
| |
Collapse
|
6
|
Chang MJ, Samlowski W, Fife D, Machan M, Meoz R. CLO23-068: Effectiveness and Toxicity of Cetuximab With Concurrent Radiotherapy in Locally Advanced Cutaneous Squamous Cell Skin Cancer: A Case Series. J Natl Compr Canc Netw 2023. [DOI: 10.6004/jnccn.2022.7250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
7
|
Sadrolashrafi K, Samlowski W. Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission. Oncologist 2023; 28:e270-e275. [PMID: 36852837 PMCID: PMC10166161 DOI: 10.1093/oncolo/oyad016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Accepted: 12/29/2022] [Indexed: 03/01/2023] Open
Abstract
INTRODUCTION Checkpoint blockade has improved the response rate and survival in metastatic melanoma. Elective treatment discontinuation appears to be reasonable in most patients who have achieved a confirmed complete remission. It seems crucial to understand whether restarting immune checkpoint inhibitor therapy can induce additional responses or remissions in rare patients who relapse. METHODS A retrospective analysis identified only 10 patients who relapsed after elective treatment discontinuation after a radiologically confirmed remission. These patients were retreated with single-agent PD-1 or combined CTLA-4 plus PD-1-directed monoclonal antibodies. RESULTS We found an initial complete response rate of 20% (2 patients) following retreatment. With a median follow-up of 26 months, the addition of individualized salvage therapies converted an additional 4 patients to a 2nd remission. All 6 of these patients have again discontinued therapy. Three patients have died of metastatic melanoma, while another is receiving salvage therapy. Six of our 10 patients experienced grades 2-3 retreatment-related toxicity. There were no hospitalizations or fatalities. DISCUSSION Retreatment of relapsing patients resulted in 20% complete responses with checkpoint inhibitors. The planned addition of other treatment modalities converted another 4 patients (40%) to a durable 2nd remission. This sequential approach merits further exploration in prospective clinical trials.
Collapse
Affiliation(s)
| | - Wolfram Samlowski
- Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, USA.,Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.,University of Nevada School of Medicine, Reno, NV, USA
| |
Collapse
|
8
|
Samlowski W, Silver MA, Hohlbauch A, Zhang S, Scherrer E, Fukunaga-Kalabis M, Krepler C, Jiang R. Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics. Future Oncol 2022; 18:3755-3767. [PMID: 36346064 DOI: 10.2217/fon-2022-0508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Aim: To describe clinical outcomes after complete surgical resection of stage IIB and IIC melanoma. Methods: Adult patients (n = 567) with stage IIB or IIC cutaneous melanoma initially diagnosed and completely resected from 2008-2017 were identified using data from a US community-based oncology network. Results: Median patient follow-up was 38.8 months from melanoma resection to death, last visit or data cut-off (31 December 2020). For stage IIB (n = 375; 66%), Kaplan-Meier median real-world recurrence-free survival (rwRFS) was 58.6 months (95% CI, 48.6-69.5). For stage IIC (n = 192; 34%), median rwRFS was 29.9 months (24.9-45.5). Overall, 44% of patients had melanoma recurrence or died; 30% developed distant metastases. Conclusion: Melanoma recurrence was common, highlighting the need for effective adjuvant therapy for stage IIB and IIC melanoma.
Collapse
Affiliation(s)
- Wolfram Samlowski
- Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148 USA/The US Oncology Network.,University of Nevada School of Medicine, Reno, NV 89557 USA.,University of Nevada Las Vegas, Las Vegas, NV 89102, USA
| | | | | | - Shujing Zhang
- Biostatistics & Research Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA
| | - Emilie Scherrer
- Center for Observational & Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ 07065, USA
| | | | | | - Ruixuan Jiang
- Center for Observational & Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ 07065, USA
| |
Collapse
|
9
|
Samlowski W, Robert NJ, Chen L, Schenkel B, Davis C, Moshyk A, Kotapati S, Poretta T, Weber JS. Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma. Cancer Med 2022; 12:2378-2388. [PMID: 35880244 PMCID: PMC9939122 DOI: 10.1002/cam4.5061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 06/10/2022] [Accepted: 07/08/2022] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real-world data on this regimen are limited in this setting. METHODS This retrospective observational study utilized data from the US Oncology Network iKnowMed electronic health record database and patient medical charts. Eligible patients were diagnosed with melanoma and received adjuvant nivolumab monotherapy from March to August 2018. Patients were grouped by dosing regimen: cohort 1 (C1), de novo nivolumab 480 mg Q4W; cohort 2 (C2), switched to nivolumab 480 mg Q4W after nivolumab 240 mg or 3 mg/kg every 2 weeks (Q2W); cohort 3 (C3), de novo nivolumab 3 mg/kg Q2W; or cohort 4 (C4), de novo nivolumab 240 mg Q2W. Patients were followed for up to 12 months. Duration of therapy and safety/tolerability were assessed. RESULTS One hundred ninety-one patients were included (C1, n = 40; C2, n = 74; C3, n = 22; C4, n = 55). Duration of therapy was relatively consistent across cohorts (median, 10.3 months; range, 8.3-10.7). Likewise, proportions of patients experiencing treatment-related adverse events (TRAEs) were similar (range, 54.5%-60.1%), as were the most common events (fatigue, rash, diarrhea, hypothyroidism, nausea, and pruritus). However, proportions experiencing 'significant' TRAEs varied between cohorts. Proportions discontinuing treatment were relatively consistent across cohorts. Propensity score matching and sensitivity analyses generally supported the unadjusted findings. CONCLUSIONS Real-world safety profiles of nivolumab 240 mg Q2W and 480 mg Q4W were similar, and both were comparable to the well-documented safety of weight-based dosing (3 mg/kg Q2W), further supporting their approval and use in the adjuvant setting for melanoma.
Collapse
Affiliation(s)
- Wolfram Samlowski
- Comprehensive Cancer Centers of Nevada and University of Nevada Las Vegas Kirkorian School of MedicineLas VegasNevadaUSA,University of Nevada School of MedicineRenoNevadaUSA
| | | | - Liwei Chen
- McKesson Life SciencesThe WoodlandsTexasUSA
| | | | | | | | | | | | - Jeffrey S. Weber
- Perlmutter Cancer CenterNYU School of MedicineNew YorkNew YorkUSA
| |
Collapse
|
10
|
Perez L, Samlowski W, Lopez-Flores R. Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data. Biomedicines 2022; 10:biomedicines10051144. [PMID: 35625881 PMCID: PMC9138966 DOI: 10.3390/biomedicines10051144] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 05/02/2022] [Accepted: 05/12/2022] [Indexed: 12/18/2022] Open
Abstract
Checkpoint inhibitor therapy for metastatic melanoma has dramatically improved outcomes. Currently, 20 to 40% of treated patients achieve lengthy remissions. It is not clear whether patients in remission require ongoing therapy or if treatment can be safely discontinued. A retrospective chart review was performed of patients who underwent elective treatment discontinuation after two negative scans three months apart. Of 132 checkpoint inhibitor-treated patients, 46 achieved a complete response (34.8%) and electively discontinued therapy. The progression-free survival was 97.5% at 1 year and 94.7% at 3 years following treatment discontinuation. The median duration of follow-up was 26 months. In total, 4 of 46 individuals (8.7%) eventually relapsed (median time to relapse: 27 months). The median disease-specific survival of the entire cohort was not reached and was 100% at 4 years from the start of therapy. Two patients eventually died, one from melanoma and the other from an unrelated illness. We have identified an elective treatment discontinuation strategy that is generalizable to a variety of checkpoint inhibitor ± targeted therapy regimens. We found that most complete remissions remained durable after elective treatment discontinuation. We hypothesize that this approach could decrease potential drug toxicities, reduce the treatment-related financial burden, and improve patients’ quality of life.
Collapse
Affiliation(s)
- Leanne Perez
- University of Nevada School of Medicine, Reno, NV 89557, USA; (L.P.); (R.L.-F.)
| | - Wolfram Samlowski
- University of Nevada School of Medicine, Reno, NV 89557, USA; (L.P.); (R.L.-F.)
- Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA
- Department of Internal Medicine, Las Vegas Kerkorian School of Medicine, University of Nevada, Las Vegas, NV 89102, USA
- Correspondence: ; Tel.: +1-702-321-3930
| | - Ruby Lopez-Flores
- University of Nevada School of Medicine, Reno, NV 89557, USA; (L.P.); (R.L.-F.)
| |
Collapse
|
11
|
Lopez-Flores R, Samlowski W, Perez L. Elective Checkpoint Inhibitor Discontinuation in Metastatic Solid Tumor Patients: A Case Series. Ann Case Rep 2022; 7:894. [PMID: 36506754 PMCID: PMC9732972 DOI: 10.29011/2574-7754.100894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Introduction Checkpoint inhibitor (CKI) therapy has markedly altered the survival of patients with many solid tumors. It appears clear that 10-40% of patients with a number of metastatic cancers can achieve lengthy remissions following CKI therapy. The optimal duration of treatment or whether treatment can ever be safely stopped is still controversial. Based on melanoma-derived data, we tested whether CKI treatment could safely be discontinued in patients with other solid tumors. Methods A retrospective analysis was performed in adults with metastatic solid tumors treated with CKI-based therapy. Patients with solid tumors who achieved complete remission on 2 sequential scans at least 3 months apart during ongoing treatment were identified from our computerized patient database. Patient data was analyzed for patient characteristics, as well as progression-free and overall survival. Results A total of 69 non-melanoma solid tumor patients were treated with CKI-based regimens in our clinic and 14 achieved complete remission (20.3%). Five patients were female (35.7%) and the remaining nine were male (64.3%). A 100% progression-free survival was observed for these patients. The median duration of complete remission was over 20 months from the time of elective treatment discontinuation. Median overall survival was not reached in this cohort. One patient died of no cancer-related causes. Conclusions Based on this retrospective case series, elective treatment discontinuation in patients who achieved complete remission appears feasible. All patients remained in a durable complete remission after treatment discontinuation. We hypothesize that appropriate selection of patients for early treatment discontinuation may decrease their economic burden related to ongoing treatment, limit potential toxicity, and improve quality of life.
Collapse
Affiliation(s)
| | - Wolfram Samlowski
- University of Nevada School of Medicine, Reno, NV, USA,Comprehensive Cancer Centers of Nevada, Las Vegas NV, USA,University of Nevada, Las Vegas Kerkorian School of Medicine Las Vegas, NV, USA,Corresponding author: Wolfram Samlowski, Comprehensive Cancer Centers of Nevada, 9280 W. Sunset Rd., Suite 100, Las Vegas, NV 89148, USA
| | - Leanne Perez
- University of Nevada School of Medicine, Reno, NV, USA
| |
Collapse
|
12
|
Samlowski W, Adajar C. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. BMC Cancer 2021; 21:1187. [PMID: 34743688 PMCID: PMC8573907 DOI: 10.1186/s12885-021-08906-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Accepted: 10/25/2021] [Indexed: 12/11/2022] Open
Abstract
Background Virtually all metastatic patients with metastatic melanoma who progress after initial treatment with PD-1 or CTLA-4 directed antibodies will die of their disease. Salvage options are urgently needed. It is theoretically attractive to combine immunotherapy with targeted agents in progressing patients with BRAF mutation positive melanoma, but the toxicity of combined treatment has proven challenging. Methods We performed a retrospective analysis of our patient database and identified 23 patients who progressed on initial checkpoint inhibitor treatment, who subsequently had cautious addition of BRAF±MEK inhibitor therapy to continued PD-1 antibody treatment. Results We found an objective response rate of 55% in second line therapy, with a median progression-free survival of 33.4 months and median overall survival of 34.1 months, with 40% of patients in unmaintained remission at over 3 years. Ten of 12 responding patients were able to discontinue all therapy and continue in unmaintained remission. Toxicity of this approach was generally manageable (21.7% grade 3–5 toxicity). There was 1 early sudden death for unknown reasons in a responding patient. Discussion Our results suggest that 2nd line therapy with PD-1 inhibitors plus BRAF±MEK inhibitors has substantial activity and manageable toxicity. This treatment can induce additional durable complete responses in patients who have progressed on initial immunotherapy. These results suggest further evaluation be performed of sequential PD-1 antibody treatment with cautious addition of targeted therapy in appropriate patients.
Collapse
Affiliation(s)
- Wolfram Samlowski
- Comprehensive Cancer Centers of Nevada, 9280 W. Sunset Rd., Suite 100, Las Vegas, NV, 89148, USA. .,University of Nevada Las Vegas, (UNLV) Kerkorian School of Medicine, Las Vegas, NV, USA. .,University of Nevada School of Medicine, Reno, NV, USA.
| | - Camille Adajar
- University of Nevada Las Vegas, (UNLV) Kerkorian School of Medicine, Las Vegas, NV, USA
| |
Collapse
|
13
|
Weissman JP, Samlowski W, Meoz R. Hedgehog Inhibitor Induction with Addition of Concurrent Superficial Radiotherapy in Patients with Locally Advanced Basal Cell Carcinoma: A Case Series. Oncologist 2021; 26:e2247-e2253. [PMID: 34472658 DOI: 10.1002/onco.13959] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2021] [Accepted: 08/19/2021] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND Locally advanced basal cell cancer is a rare and challenging clinical problem. Historically, these patients were treated with aggressive surgery or radiotherapy. Most sporadic basal cell carcinomas have somatic mutations in the hedgehog pathway. Oral hedgehog inhibitors induce rapid and often complete clinical responses in locally advanced basal cell tumors. Unfortunately, these responses are usually transient. We hypothesized that treatment failure represents persistence of drug resistant cells that could be eradicated by addition of localized radiotherapy. MATERIALS AND METHODS We performed a retrospective review of our patients with locally advanced basal cell cancer treated with sonidegib or vismodegib induction therapy who were treated with added superficial radiotherapy at the time of maximal response. RESULTS Twelve patients met inclusion criteria. All patients achieved a complete response following hedgehog inhibitor therapy with addition of radiotherapy. Progression-free survival at 40 months was 89%, with a median follow-up of 40 months. Relapses occurred in only 2 of 12 patients (16.6%). Nine patients experienced grade I-II toxicity from hedgehog inhibitor induction therapy (taste changes [3], weight loss [3], muscle cramps [3]). Eight patients experienced mild radiotherapy-induced skin toxicity during concurrent therapy. No patients had to discontinue treatment. CONCLUSION Induction therapy with hedgehog inhibitors followed by addition of concurrent radiation therapy resulted in an extremely high clinical response rate with relatively minor and reversible toxicity. This gave a high rate of progression-free survival and a low disease-specific progression rate. Further prospective evaluation of this treatment approach is needed to confirm the apparent clinical activity. IMPLICATIONS FOR PRACTICE Locally advanced basal cell cancers are challenging to treat. Previously, aggressive surgical resection or radiotherapy represented the best treatment options. Most basal cell cancers have somatic mutations in the hedgehog pathway. Oral inhibitors of this pathway produce rapid but transient clinical responses. This study reports 12 patients treated with hedgehog inhibitor induction therapy to near-maximal response. Addition of concurrent involved field radiotherapy resulted in a very high complete response rate with minimal toxicity. There was prolonged progression-free survival in 90% of patients. This study identified a novel treatment approach for patients with advanced basal cell carcinoma.
Collapse
Affiliation(s)
- Joshua P Weissman
- Feinberg School of Medicine, Northwestern University, Evanston, Illinois, USA.,Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA
| | - Wolfram Samlowski
- Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA.,School of Medicine, University of Nevada, Las Vegas, Las Vegas, Nevada, USA.,University of Nevada School of Medicine, Reno, Nevada, USA
| | - Raul Meoz
- Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA.,School of Medicine, University of Nevada, Las Vegas, Las Vegas, Nevada, USA.,University of Nevada School of Medicine, Reno, Nevada, USA
| |
Collapse
|
14
|
Samlowski W, Robert NJ, Nwokeji ED, Baidoo B, Schenkel B, Moshyk A, Kotapati S, Poretta T, Weber JS. Abstract 1043: Real-world outcomes in patients receiving nivolumab 480 mg every 4 weeks vs other dosing regimens as treatment for melanoma in the adjuvant setting. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-1043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Nivolumab is approved for the adjuvant treatment of melanoma, and a 480 mg every 4 weeks (Q4W) flat-dosing monotherapy regimen was approved in the United States (March 2018). We examined real-world outcomes with different adjuvant nivolumab dosing regimens in a US community oncology setting.
Methods: We conducted a retrospective chart review of US Oncology Network iKnowMed™ electronic health records of patients with melanoma receiving nivolumab from March 1, 2018, to February 28, 2019. Patients were grouped by nivolumab regimen: cohort 1 (C1), nivolumab 480 mg Q4W de novo (no prior nivolumab treatment); cohort 2 (C2), switched to nivolumab 480 mg Q4W after receiving nivolumab 240 mg or 3 mg/kg every 2 weeks (Q2W); cohort 3 (C3), nivolumab 3 mg/kg Q2W de novo; or cohort 4 (C4), nivolumab 240 mg Q2W de novo. Patients were followed for ≥6 months after nivolumab initiation. Treatment patterns and safety outcomes were compared between cohorts. Propensity score matching was performed to minimize potential selection bias (C1:C4 and C2:C4).
Results: A total of 191 patients with melanoma were identified (C1, n=40; C2, n=74; C3, n=22; C4, n=55). Baseline demographic and clinical characteristics were similar in all 4 cohorts, however, C3 patients had the lowest mean body mass index (25.8 kg/m2) and the lowest proportion of patients with Eastern Cooperative Oncology Group performance status of 0 (32%). Duration of treatment and incidence of treatment-related adverse events (TRAEs) and severe TRAEs were similar across all unadjusted cohorts (Table). These results were supported by matched cohort analyses (C1:C4 and C2:C4). Rates of treatment completion (12-month course) or ongoing treatment and reasons for discontinuation varied by cohort (Table).
TableCohort 1Cohort 2Cohort 3Cohort 4Outcomes: unadjusted study populationNIVO 480 mg Q4W (de novo) N=40NIVO 480 mg Q4W (switched) N=74NIVO 3 mg/kg Q2W (de novo) N=22NIVO 240 mg Q2W (de novo) N=55Median DoT, months (95% CI)aNR (5.3-NE)9.5 (7.5-11.1)8.3 (5.2-11.7)10.8 (10.6-NE)Completed planned 12-month treatment or treatment is ongoing, %73735971Most common reasons for treatment discontinuation, %Progression1031418Toxicityb131196Patient preference0592Physician preference0400Severe TRAE, %c,d1081811Any TRAE, %d55575556Fatigue33242331Rash15181813Diarrhea1016913Hypothyroidism155511Pruritus5854Nausea5456aDoT was defined as the interval between the date of initiation of nivolumab and the last administration date, including treatment holidays or other breaks no more than 180 consecutive days in length; P=0.5797 (calculated from a test analogous to McNemar's test for correlated binary proportions [Klein and Moeschberger,1997]).bToxicity resulting in discontinuation may or may not be an AE that was explicitly attributed to NIVO.cAEs explicitly attributed to NIVO dosing regimen that led to dose withheld, dose modification, dose permanently discontinued, hospitalization, or emergency department visit. AE severity was based in part on the CTCAE v.5.0 grading system, and dose modifications were recommended in cases of adverse reactions listed in the package insert.dOccurring within 6 months from treatment initiation.AE, adverse event; CI, confidence interval; DoT, duration of treatment; NE, not estimable; NIVO, nivolumab; NR, not reached.
Conclusions: This real-world data analysis of nivolumab dosing regimens shows that duration of therapy and AEs are similar between the Q2W and Q4W regimens in patients with melanoma.
Citation Format: Wolfram Samlowski, Nicholas J. Robert, Esmond D. Nwokeji, Bismark Baidoo, Brad Schenkel, Andriy Moshyk, Srividya Kotapati, Tayla Poretta, Jeffrey S. Weber. Real-world outcomes in patients receiving nivolumab 480 mg every 4 weeks vs other dosing regimens as treatment for melanoma in the adjuvant setting [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1043.
Collapse
|
15
|
Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJL, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 2014; 20:2457-65. [PMID: 24634374 DOI: 10.1158/1078-0432.ccr-13-3017] [Citation(s) in RCA: 172] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
PURPOSE It has been demonstrated that large numbers of tumor-specific T cells for adoptive cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous peripheral blood lymphocytes and expanding them over several weeks. In mouse models, this therapy is optimized when administered with dendritic cell (DC) vaccination. We developed a short 1-week manufacture protocol to determine the feasibility, safety, and antitumor efficacy of this double cell therapy. EXPERIMENTAL DESIGN A clinical trial (NCT00910650) adoptively transferring MART-1 T-cell receptor (TCR) transgenic lymphocytes together with MART-1 peptide-pulsed DC vaccination in HLA-A2.1 patients with metastatic melanoma. Autologous TCR transgenic cells were manufactured in 6 to 7 days using retroviral vector gene transfer, and reinfused with (n = 10) or without (n = 3) prior cryopreservation. RESULTS A total of 14 patients with metastatic melanoma were enrolled and 9 of 13 treated patients (69%) showed evidence of tumor regression. Peripheral blood reconstitution with MART-1-specific T cells peaked within 2 weeks of ACT, indicating rapid in vivo expansion. Administration of freshly manufactured TCR transgenic T cells resulted in a higher persistence of MART-1-specific T cells in the blood as compared with cryopreserved. Evidence that DC vaccination could cause further in vivo expansion was only observed with ACT using noncryopreserved T cells. CONCLUSION Double cell therapy with ACT of TCR-engineered T cells with a very short ex vivo manipulation and DC vaccines is feasible and results in antitumor activity, but improvements are needed to maintain tumor responses.
Collapse
Affiliation(s)
- Thinle Chodon
- Authors' Affiliations: Departments of Medicine, Surgery, Pathology and Laboratory Medicine, Microbiology, Immunology and Molecular Genetics, and Molecular and Medical Pharmacology; Jonsson Comprehensive Cancer Center; Department of Ophthalmology, Jules Stein Eye Institute; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research; Howard Hughes Medical Institute, University of California, Los Angeles (UCLA); The Angeles Clinic Research Institute, Los Angeles; Department of Medicine, University of California San Diego (UCSD) Moores Cancer Center, La Jolla; Divisions of Chemistry and Biology, California Institute of Technology, Pasadena, California; Department of Medical and Molecular Genetics, Indiana University, and the Indiana University Viral Production Facility (IU VPF), Indianapolis, Indiana; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada; Mayo Clinic Scottsdale, Scottsdale, Arizona; Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut; and Center for Immunology, Roswell Park Cancer Institute, Buffalo, New York
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn DI, Robison LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ. Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol 2012; 31:131-61. [PMID: 23213095 DOI: 10.1200/jco.2012.47.1938] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
A MESSAGE FROM ASCO'S PRESIDENTI am delighted to present you with “Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.” The American Society of Clinical Oncology (ASCO) uses this opportunity each year to share the steady progress occurring in our understanding and treatment of cancer. For 2012, we offer again an inspiring perspective on clinical cancer advances over the past year, but with a cautionary note: if current threats to federal funding materialize, future progress in cancer research will be seriously undermined.Continued progress against cancer. As you read the following pages of this report, I hope you will share my unabashed enthusiasm—and pride—in how far we have come. To appreciate what this progress has meant to the millions of people who receive a cancer diagnosis each year, consider the following: (1) two of three people in the United States live at least 5 years after a cancer diagnosis (up from roughly one of two in the 1970s); (2) the nation's cancer death rate has dropped 18% since the early 1990s, reversing decades of increases; and (3) individuals with cancer are increasingly able to live active, fulfilling lives because of better management of symptoms and treatments with fewer adverse effects.Importance of clinical cancer trials. These dramatic trends—and the advances highlighted in this report—would have been unthinkable without the engine that drives life-saving cancer treatment: clinical cancer research. Advances in technology and in our knowledge of how patient-specific molecular characteristics of the tumor and its environment fuel the growth of cancer have brought new hope to patients. Clinical trials are the key to translating cutting-edge laboratory discoveries into treatments that extend and improve the lives of those with cancer.But progress is only part of the story. Cancer remains a challenge, with many cancers undetected until their latest stages and others resisting most attempts at treatment. Tragically, cancer still kills more than 500,000 people in the United States every year, and its global burden is growing rapidly.Bridges to better care. To conquer cancer, we need to build bridges to the future—bridges that will get scientific advances to the patient's bedside quicker, bridges that will enable us to share information and learn what works in real time, and bridges that will improve care for all patients around the world.At ASCO, we recognize the unique role that oncologists must play. ASCO's “Accelerating Progress Against Cancer: Blueprint for Transforming Clinical and Translational Cancer Research,”1published last year, presents our vision and recommendations to make cancer research and patient care vastly more targeted, more efficient, and more effective. We have also launched a groundbreaking initiative, CancerLinQ, that aims to improve cancer care and speed research by drawing insights from the vast pool of data on patients in real-world settings.Renewing a national commitment to cancer research. We are on the threshold of major advances in cancer prevention, detection, and treatment—but only if, as a nation, we remain committed to this critical endeavor.The federally funded cancer research system is currently under threat by larger federal budget concerns. Clearly, Congress faces a complex budget environment, but now is not the time to retreat from our nation's commitment to conquering a disease that affects nearly all of us. Bold action must be taken to ensure that we can take full advantage of today's scientific and technologic opportunities.Please join me in celebrating our nation's progress against cancer and in recommitting ourselves to supporting cancer research. Millions of lives depend on it.Sandra M. Swain, MDPresidentAmerican Society of Clinical Oncology
Collapse
Affiliation(s)
- Bruce J Roth
- Washington University in St Louis, St Louis, MO, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 2012; 118:6055-62. [PMID: 22674198 DOI: 10.1002/cncr.27668] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2011] [Revised: 03/09/2012] [Accepted: 03/13/2012] [Indexed: 11/10/2022]
Abstract
BACKGROUND The clinical activity of allosteric inhibitors of mammalian target of rapamycin (mTOR) inhibitors in renal cell carcinoma (RCC) may be limited by upstream activation of phosphatidylinositol 3 (PI3)-kinase/Akt resulting from mTOR1 inhibition. On the basis of this rationale, 2 independent phase 2 trials (Perifosine 228 and 231) were conducted to assess the efficacy and safety of the novel Akt inhibitor perifosine in patients with advanced RCC who had failed on previous vascular endothelial growth factor (VEGF)-targeted therapy. METHODS In the Perifosine 228 trial, 24 patients with advanced RCC received oral perifosine (100 mg daily). Perifosine 231 enrolled 2 groups that received daily oral perifosine (100 mg daily): Group A comprised 32 patients who had received no prior mTOR inhibitor, and Group B comprised 18 patients who had received 1 prior mTOR inhibitor. RESULTS In the Perifosine 228 trial, 1 patient achieved a partial response (objective response rate, 4%; 95% confidence interval, 0.7%-20%), and 11 patients (46%) had stable disease as their best response. The median progression-free survival was 14.2 weeks (95% confidence interval, 7.7-21.6 weeks). In the Perifosine 231 trial, 5 patients achieved a partial response (objective response rate, 10%; 95% confidence interval, 4.5%-22.2%) and 16 patients (32%) had stable disease as their best response. The median progression-free survival was 14 weeks (95% confidence interval, 12.9, 20.7 weeks). Overall, perifosine was well tolerated, and there were very few grade 3 and 4 events. The most common toxicities included nausea, diarrhea, musculoskeletal pain, and fatigue. CONCLUSIONS Although perifosine demonstrated activity in patients with advanced RCC after failure on VEGF-targeted therapy, its activity was not superior to currently available second-line agents. Nonetheless, perifosine may be worthy of further study in RCC in combination with other currently available therapies.
Collapse
Affiliation(s)
- Daniel C Cho
- Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Eroglu Z, Kong KM, Jakowatz JG, Samlowski W, Fruehauf JP. Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemother Pharmacol 2011; 68:1081-7. [PMID: 21769667 PMCID: PMC3180631 DOI: 10.1007/s00280-011-1703-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2011] [Accepted: 06/30/2011] [Indexed: 11/24/2022]
Abstract
Purpose Metastatic melanoma patients have a poor prognosis. No chemotherapy regimen has improved overall survival. More effective treatments are needed. Docetaxel has clinical activity in melanoma and may be more active when combined with vinorelbine. Granulocyte–macrophage colony-stimulating factor (GM-CSF) has shown activity as an adjuvant melanoma therapy. We carried out a phase II study of these agents in patients with stage IV melanoma. Methods Patients had documented stage IV melanoma and may have had prior immuno or chemotherapy. Previously treated brain metastases were allowed. Docetaxel (40 mg/m2 IV) and vinorelbine (30 mg/m2 IV) were administered every 14 days, followed by GM-CSF (250 mg/m2 SC on days 2 to 12). The primary endpoint of the study was 1-year overall survival (OS). Secondary objectives were median overall survival, response rate (per RECIST criteria), and the toxicity profiles. Results Fifty-two patients were enrolled; 80% had stage M1c disease. Brain metastases were present in 21%. Fifty-two percent of patients had received prior chemotherapy, including 35% who received prior biochemotherapy. Toxicity was manageable. Grade III/IV toxicities included neutropenia (31%), anemia (14%), febrile neutropenia (11.5%), and thrombocytopenia (9%). DVS chemotherapy demonstrated clinical activity, with a partial response in 15%, and disease stabilization in 37%. Six-month PFS was 37%. Median OS was 11.4 months and 1-year OS rate was 48.1%. Conclusions The DVS regimen was active in patients with advanced, previously treated melanoma, with manageable toxicity. The favorable 1-year overall survival and median survival rates suggest that further evaluation of the DVS regimen is warranted.
Collapse
Affiliation(s)
- Zeynep Eroglu
- Departments of Medicine, University of California Irvine Medical Center, Orange, CA 92868, USA
| | | | | | | | | |
Collapse
|
19
|
Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009; 27:5788-93. [PMID: 19884559 DOI: 10.1200/jco.2008.18.8821] [Citation(s) in RCA: 83] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
PURPOSE Patients with advanced papillary renal cell cancer (pRCC) have poor survival after systemic therapy; the reported median survival time is 7 to 17 months. In this trial, we evaluated the efficacy of erlotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in patients with advanced pRCC, a tumor type associated with wild-type von Hippel Lindau gene. PATIENTS AND METHODS Patients with histologically confirmed, advanced, or metastatic pRCC were treated with erlotinib 150 mg orally once daily. A RECIST (Response Evaluation Criteria in Solid Tumors) response rate (RR) of > or = 20% was considered a promising outcome. Secondary end points included overall survival and 6-month probability of treatment failure. RESULTS Of 52 patients registered, 45 were evaluable. The overall RR was 11% (five of 45 patients; 95% CI, 3% to 24%), and the disease control rate was 64% (ie five partial response and 24 stable disease). The median overall survival time was 27 months (95% CI, 13 to 36 months). Probability of freedom from treatment failure at 6 months was 29% (95% CI, 17% to 42%). There was one grade 5 adverse event (AE) of pneumonitis, one grade 4 thrombosis, and nine other grade 3 AEs. CONCLUSION Although the RECIST RR of 11% did not exceed prespecified estimates for additional study, single-agent erlotinib yielded disease control and survival outcomes of interest with an expected toxicity profile. The design of future trials of the EGFR axis in pRCC should be based on preclinical or molecular data that define appropriate patient subgroups, new drug combinations, or potentially more active alternative schedules.
Collapse
|
20
|
Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E, Gonzalez R. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 2009; 29:161-6. [PMID: 19830389 DOI: 10.1007/s10637-009-9333-6] [Citation(s) in RCA: 100] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2009] [Accepted: 09/24/2009] [Indexed: 11/25/2022]
Abstract
UNLABELLED Melanoma continues to be a major health problem with no effective therapy. Melanocytes, both benign and malignant, express many anti-apoptotic factors. Survivin is a member of the family of inhibitors of apoptosis proteins (IAP) and is preferentially expressed in tumor cells, including melanoma. YM155 is a small molecule suppressant of survivin that has been shown in preclinical cell lines, xenograft models and phase I studies to have anti-tumor activity. METHODS This was an open-label, multi-center, study of YM155 monotherapy in subjects with unresectable stage III or IV melanoma. Thirty-four chemotherapy naïve subjects were treated with YM155 at a dose of 4.8 mg/m(2)/day administered by continuous infusion for 168-hours (7 days) followed by a 14-day rest period, for up to 6 cycles or until disease progression. RESULTS One subject had a partial response to treatment seen at cycle two and lasting through cycle eight. Median progression-free survival was 1.3 months (95% CI; 1.3-2.7). Median overall survival was 9.9 months (95% CI; 7.0-14.5). Overall, YM155 was well tolerated with the most common (>20%) adverse events reported as fatigue, nausea, pyrexia, headache, arthralgia and back pain. Only four subjects required dose reductions. CONCLUSIONS YM155 was well tolerated in subjects with advanced melanoma; however, the pre-specified primary end-point for efficacy which required two responders in 29 evaluable subjects was not achieved.
Collapse
Affiliation(s)
- Karl D Lewis
- University of Colorado Health Sciences Center, Aurora, CO, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
|
22
|
Eliason M, Bowen A, Hazard L, Samlowski W. Primary Treatment of Verrucous Carcinoma of the Penis With Fluorouracil, cis-Diamino-dichloro-platinum, and Radiation Therapy. ACTA ACUST UNITED AC 2009; 145:950-2. [DOI: 10.1001/archdermatol.2009.160] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
23
|
Vogelzang NJ, Hutson TE, Samlowski W, Somer B, Richey S, Alemany C, Loesch D, Richards P, Gardner L, Sportelli P. Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5034] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5034 Background: Perifosine, a synthetic alkylphospholipid, inhibits or modulates a number of different signal transduction pathways (AKT, MAPK and JNK). In a prior trial, 15 RCC patients (pts) were enrolled in a randomized dose finding study, 9 were evaluable for response and 3 (33%) had a partial response (PR). Thus phase II trials were begun for pts who had been treated with one prior VEGFr inhibitor (Group A) or with a prior VEGFr inhibitor and prior mTOR inhibitor (Group B). We report the results of Group A (closed), and Group B (enrollment open). Methods: To measure the objective response rate (RECIST) and PFS to single agent perifosine (100 mg qhs with food) after 3 mos of Rx; Prior Rx with vaccine therapy, bevacizumab and/or cytokines was permitted. Normal organ/marrow function was required. Results: From 12/07–12/08, 46 pts (31 Group A/ 15 Group B) were treated at 13 sites. Median age 64 (range 46–80) and 36 were male; Median prior Rx was 2 (range 1 - 5); Clear cell = 37, non clear cell = 6, data n/a = 3. Prior sunitinib = 35, prior sorafenib = 10, 1 unknown due to blinded study. Prior mTOR; Tem = 9 and Rad001 = 6. As of 12/08, 44 pts were evaluable for response and PFS (two pts not eval; 1 withdrew consent, 1 toxicity < 5 days on Rx). Results listed in the table below. As of 12/08, 12/44 pts (5 Group A/ 7 Group B) remain on treatment. Median survival; not reached. Most common toxicity was grade 1 & 2 nausea (56%), arthralgia (47%), vomiting (36%), fatigue (33%) and cognitive changes (28%). Grade 3 & 4 toxicity was uncommon; arthralgia (14%) and hyperuricemia/gout (8%). Conclusions: Perifosine, similar to mTOR inhibitors, appears to have clinical benefit in mRCC as reflected by the PR rate and a 15 wk median overall PFS. This is most notably in patients who failed both a prior VEGFr and mTOR inhibitor where 7/14 remain on study as of 12/08. Randomized studies are under consideration to further evaluate perifosine's clinical benefit as 2nd or 3rd line therapy of mRCC. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- N. J. Vogelzang
- Nevada Cancer Institute, Las Vegas, NV; Baylor Sammons Cancer Center/TOPA, Dallas, TX; West Clinic, Memphis, TN; Cancer Centers of Florida/US Oncology, Orlando, FL; Central Indiana Cancer Centers/US Oncology, Indianapolis, IN; Onc Hem Assoc SW Virginia/US Oncology, Salem, VA; Keryx Biopharmaceuticals, New York, NY
| | - T. E. Hutson
- Nevada Cancer Institute, Las Vegas, NV; Baylor Sammons Cancer Center/TOPA, Dallas, TX; West Clinic, Memphis, TN; Cancer Centers of Florida/US Oncology, Orlando, FL; Central Indiana Cancer Centers/US Oncology, Indianapolis, IN; Onc Hem Assoc SW Virginia/US Oncology, Salem, VA; Keryx Biopharmaceuticals, New York, NY
| | - W. Samlowski
- Nevada Cancer Institute, Las Vegas, NV; Baylor Sammons Cancer Center/TOPA, Dallas, TX; West Clinic, Memphis, TN; Cancer Centers of Florida/US Oncology, Orlando, FL; Central Indiana Cancer Centers/US Oncology, Indianapolis, IN; Onc Hem Assoc SW Virginia/US Oncology, Salem, VA; Keryx Biopharmaceuticals, New York, NY
| | - B. Somer
- Nevada Cancer Institute, Las Vegas, NV; Baylor Sammons Cancer Center/TOPA, Dallas, TX; West Clinic, Memphis, TN; Cancer Centers of Florida/US Oncology, Orlando, FL; Central Indiana Cancer Centers/US Oncology, Indianapolis, IN; Onc Hem Assoc SW Virginia/US Oncology, Salem, VA; Keryx Biopharmaceuticals, New York, NY
| | - S. Richey
- Nevada Cancer Institute, Las Vegas, NV; Baylor Sammons Cancer Center/TOPA, Dallas, TX; West Clinic, Memphis, TN; Cancer Centers of Florida/US Oncology, Orlando, FL; Central Indiana Cancer Centers/US Oncology, Indianapolis, IN; Onc Hem Assoc SW Virginia/US Oncology, Salem, VA; Keryx Biopharmaceuticals, New York, NY
| | - C. Alemany
- Nevada Cancer Institute, Las Vegas, NV; Baylor Sammons Cancer Center/TOPA, Dallas, TX; West Clinic, Memphis, TN; Cancer Centers of Florida/US Oncology, Orlando, FL; Central Indiana Cancer Centers/US Oncology, Indianapolis, IN; Onc Hem Assoc SW Virginia/US Oncology, Salem, VA; Keryx Biopharmaceuticals, New York, NY
| | - D. Loesch
- Nevada Cancer Institute, Las Vegas, NV; Baylor Sammons Cancer Center/TOPA, Dallas, TX; West Clinic, Memphis, TN; Cancer Centers of Florida/US Oncology, Orlando, FL; Central Indiana Cancer Centers/US Oncology, Indianapolis, IN; Onc Hem Assoc SW Virginia/US Oncology, Salem, VA; Keryx Biopharmaceuticals, New York, NY
| | - P. Richards
- Nevada Cancer Institute, Las Vegas, NV; Baylor Sammons Cancer Center/TOPA, Dallas, TX; West Clinic, Memphis, TN; Cancer Centers of Florida/US Oncology, Orlando, FL; Central Indiana Cancer Centers/US Oncology, Indianapolis, IN; Onc Hem Assoc SW Virginia/US Oncology, Salem, VA; Keryx Biopharmaceuticals, New York, NY
| | - L. Gardner
- Nevada Cancer Institute, Las Vegas, NV; Baylor Sammons Cancer Center/TOPA, Dallas, TX; West Clinic, Memphis, TN; Cancer Centers of Florida/US Oncology, Orlando, FL; Central Indiana Cancer Centers/US Oncology, Indianapolis, IN; Onc Hem Assoc SW Virginia/US Oncology, Salem, VA; Keryx Biopharmaceuticals, New York, NY
| | - P. Sportelli
- Nevada Cancer Institute, Las Vegas, NV; Baylor Sammons Cancer Center/TOPA, Dallas, TX; West Clinic, Memphis, TN; Cancer Centers of Florida/US Oncology, Orlando, FL; Central Indiana Cancer Centers/US Oncology, Indianapolis, IN; Onc Hem Assoc SW Virginia/US Oncology, Salem, VA; Keryx Biopharmaceuticals, New York, NY
| |
Collapse
|
24
|
Jensen RL, Shrieve AF, Samlowski W, Shrieve DC. Outcomes of patients with brain metastases from melanoma and renal cell carcinoma after primary stereotactic radiosurgery. Clin Neurosurg 2008; 55:150-159. [PMID: 19248682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Affiliation(s)
- Randy L Jensen
- Huntsman Cancer Institute, Department of Neurosurgery, University of Utah, Salt Lake City, USA
| | | | | | | |
Collapse
|
25
|
Gonzalez R, Lewis K, Samlowski W, Cranmer L, Catlett J, Kirkwood J, Whitman E, Lawson D, Bartels P, Drake T. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8538] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8538 Background: In cell line studies, YM155 showed markedly potent antiproliferative activity against melanoma with 50% growth inhibition (GI50) values ranging from 0.35 nM to 910 nM. In melanoma tumor-bearing mouse xenograft models, YM155 showed significant antitumor activity including regression of tumors, at doses ranging from 1 to 10 mg/kg/day. Methods: Chemotherapy naive patients with unresectable Stage III or IV melanoma were eligible. The primary endpoint was tumor response defined by RECIST criteria. Secondary endpoints included progression-free survival and toxicity. A Simon's two stage minimax design was utilized with the first stage requiring 1 response (N=27) and a total of 2 responses required at the conclusion of stage II (N=29). Patients were considered evaluable if they completed 2 cycles. YM155 was given as a 168-hour (7-day) continuous infusion every three weeks (1 cycle) at a dose of 4.8 mg/m2/day. Results: Enrollment is complete at 34 pts in order to reach 29 evaluable with treatment ongoing. Results are available for the first 26 pts. Median age was 59 y/o, (range 29 - 88) with ECOG PS of 0–1. There is one objective response of intrabdominal lymph nodes based on Investigator assessment at Cycle 2 confirmed at Cycle 4; another patient had a minor response (24% reduction) at Cycle 6 (currently at Cycle 8). Two subjects have shown stable disease after 6 cycles and remain on study. The median number of cycles is 3 (range 1 - 9). Two of 26 pts reported a grade 3 AE considered possibly related to YM155 (chest pain - nos and catheter related thrombosis). Nineteen of 26 pts have discontinued the study (18 PD, 1 withdrew consent). Conclusions: YM155 induced responses in 2 pts and was generally well tolerated. Given this encouraging response as a single agent, studies of YM155 combined with other agents are under consideration. [Table: see text]
Collapse
Affiliation(s)
- R. Gonzalez
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - K. Lewis
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - W. Samlowski
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - L. Cranmer
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - J. Catlett
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - J. Kirkwood
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - E. Whitman
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - D. Lawson
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - P. Bartels
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| | - T. Drake
- Univ of Colorado Hosp, Aurora, CO; Huntsman Cancer Institute, Salt Lake City, UT; Arizona Cancer Center, Tucson, AZ; Washington Hospital Center, Washington, DC; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mountainside Hospital, Montclaire, NJ; Emory University School of Medicine, Atlanta, GA; Astellas Pharma U.S., Deerfield, IL
| |
Collapse
|
26
|
Pan C, Hussey M, Lara P, Mack PC, Nagle RB, Dutcher J, Samlowski W, Clark J, Crawford ED, Gordon MS. Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC)—SWOG S0317. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15516] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15516 Background: Clear cell RCC often has mutations of the von Hippel-Lindau (vHL) gene and over expression of vascular endothelial growth factor (VEGF). pRCC has mutations of c-met and not vHL. Pre-clinically, normal vHL expression is associated with greater activity of EGFR inhibitors in clear cell RCC (Clin Can Res 6:1518, 2000). PRCC has no effective treatment. Given the absence of vHL mutations we undertook a study of E in pts with pRCC. Methods: Pts with histologically confirmed advanced or metastatic pRCC with measurable disease received E 150 mg PO QD from day 1 to disease progression, pt refusal, unacceptable toxicity, or a delay of therapy >3 wks. Central path review and tissue submission for vHL gene analysis were required. The primary endpoint was response. Further study of this regimen would be considered if the observed response rate (RR) was =20% (i.e. 5+ observed responses). Results: 52 pts from 27 SWOG and 2 ECOG institutions were registered. 7 pts were ineligible (no path submission-3; incorrect histology-1; no measurable disease-2; scans outside timeframe-1). Central path review is ongoing for 7 pts, leaving 39 pts evaluable for response including 30M/9F with a median age of 60.2 y (range 27.9 to 82.3). Median follow-up was 12.8 months (range 1.5 to 35.4 m). 4 pts had confirmed PRs for a RR of 10% (95% CI: 3 - 24%). Five evaluable patients with inadequate response assessment were assumed to be non-responders. Median OS was 26.9 months (95% CI lower limit 12.8 m, upper limit not yet estimable). Probability of freedom from treatment failure at 6 m is 30% (95% CI: 15–45%). There was one Grade 5 adverse event (AE) of pneumonitis thought to be possibly drug-related and one Grade 4 thrombotic AE. 8 pts experienced Grade 3 AEs common to E including rash, anorexia, diarrhea and fatigue. vHL mutation was observed in two patients with stable disease. Conclusions: Though the observed RR in pts with pRCC receiving E is similar to pts with clear cell RCC we did not see enough responses to warrant further study. As this is the first phase II trial reported (to our knowledge) for the subset of pts with pRCC we have demonstrated that less common and distinct histological subtypes can be independently studied in the cooperative group setting. [Table: see text]
Collapse
Affiliation(s)
- C. Pan
- Univ of California at Davis, Sacramento, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona, Tucson, AZ; Our Lady of Mercy Medical Center, Bronx, NY; University of Utah, Salt Lake City, UT; Loyola University School of Medicine, Chicago, IL; University of Colorado, Aurora, CO; Premiere Oncology of Arizona, Scottsdale, AZ
| | - M. Hussey
- Univ of California at Davis, Sacramento, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona, Tucson, AZ; Our Lady of Mercy Medical Center, Bronx, NY; University of Utah, Salt Lake City, UT; Loyola University School of Medicine, Chicago, IL; University of Colorado, Aurora, CO; Premiere Oncology of Arizona, Scottsdale, AZ
| | - P. Lara
- Univ of California at Davis, Sacramento, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona, Tucson, AZ; Our Lady of Mercy Medical Center, Bronx, NY; University of Utah, Salt Lake City, UT; Loyola University School of Medicine, Chicago, IL; University of Colorado, Aurora, CO; Premiere Oncology of Arizona, Scottsdale, AZ
| | - P. C. Mack
- Univ of California at Davis, Sacramento, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona, Tucson, AZ; Our Lady of Mercy Medical Center, Bronx, NY; University of Utah, Salt Lake City, UT; Loyola University School of Medicine, Chicago, IL; University of Colorado, Aurora, CO; Premiere Oncology of Arizona, Scottsdale, AZ
| | - R. B. Nagle
- Univ of California at Davis, Sacramento, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona, Tucson, AZ; Our Lady of Mercy Medical Center, Bronx, NY; University of Utah, Salt Lake City, UT; Loyola University School of Medicine, Chicago, IL; University of Colorado, Aurora, CO; Premiere Oncology of Arizona, Scottsdale, AZ
| | - J. Dutcher
- Univ of California at Davis, Sacramento, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona, Tucson, AZ; Our Lady of Mercy Medical Center, Bronx, NY; University of Utah, Salt Lake City, UT; Loyola University School of Medicine, Chicago, IL; University of Colorado, Aurora, CO; Premiere Oncology of Arizona, Scottsdale, AZ
| | - W. Samlowski
- Univ of California at Davis, Sacramento, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona, Tucson, AZ; Our Lady of Mercy Medical Center, Bronx, NY; University of Utah, Salt Lake City, UT; Loyola University School of Medicine, Chicago, IL; University of Colorado, Aurora, CO; Premiere Oncology of Arizona, Scottsdale, AZ
| | - J. Clark
- Univ of California at Davis, Sacramento, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona, Tucson, AZ; Our Lady of Mercy Medical Center, Bronx, NY; University of Utah, Salt Lake City, UT; Loyola University School of Medicine, Chicago, IL; University of Colorado, Aurora, CO; Premiere Oncology of Arizona, Scottsdale, AZ
| | - E. D. Crawford
- Univ of California at Davis, Sacramento, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona, Tucson, AZ; Our Lady of Mercy Medical Center, Bronx, NY; University of Utah, Salt Lake City, UT; Loyola University School of Medicine, Chicago, IL; University of Colorado, Aurora, CO; Premiere Oncology of Arizona, Scottsdale, AZ
| | - M. S. Gordon
- Univ of California at Davis, Sacramento, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona, Tucson, AZ; Our Lady of Mercy Medical Center, Bronx, NY; University of Utah, Salt Lake City, UT; Loyola University School of Medicine, Chicago, IL; University of Colorado, Aurora, CO; Premiere Oncology of Arizona, Scottsdale, AZ
| |
Collapse
|
27
|
Weber J, Samlowski W, Stephenson J, Ribas A, O??Day S, Rene G, Dorr R, Grenier K, Hersh E. Phase I/II trial of Amplimexon (imexon, inj.) plus dacarbazine in patients with stage III or IV malignant melanoma. Melanoma Res 2006. [DOI: 10.1097/00008390-200609001-00157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 2006; 107:319-27. [PMID: 16779801 DOI: 10.1002/cncr.21994] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Previous data from an institutional pilot study in patients with advanced or recurrent squamous cell carcinoma of the head and neck (SCCHN) who received treated a combined chemotherapy regimen of paclitaxel, cisplatin, and 5-fluorouracil indicated an overall response rate of 60% and a median survival of 6 months. To validate these results and to determine the feasibility of this combination, a Phase II study was conducted by the Southwest Oncology Group (SWOG S0007). METHODS Patients with advanced or recurrent SCCHN were eligible if they had received 1 previous regimen of induction/adjuvant chemotherapy or no prior systemic therapy. Patients received treatment with paclitaxel (135 mg/m(2) on Day 1), followed by cisplatin (75 mg/m(2) on Day 1), and 5-fluorouracil (1000 mg/m(2)per day as a 96-hour continuous infusion on Days 1-4) every 21 days. RESULTS Seventy-six patients received a combined total of 286 cycles of chemotherapy. Sixty-nine patients were evaluable for response. There were 5 complete responses (7%) and 23 partial responses (33%) partial responses, for an overall response rate of 41%. The median progression-free survival was 4 months, and the median overall survival was 10 months. Six treatment-related deaths were documented, including deaths in 2 patients who had a Zubrod PS of 2. Grade 3 or 4 neutropenia (according to National Cancer Institute Common Toxicity Criteria [version 2.0]) was observed in 47% of patients. Other Grade 3 or 4 adverse events included mucositis (34% of patients), nausea (20% of patients), anemia (9% of patients), and neuropathy (8% of patients). CONCLUSIONS The combination of paclitaxel, cisplatin, and 5-fluorouracil had efficacy similar to that of standard treatment regimens in patients with advanced or recurrent SCCHN but with increased toxicity.
Collapse
Affiliation(s)
- Francis P Worden
- Department of Internal Medicine, Division of Medical Oncology, University of Michigan, Ann Arbor, Michigan 48109-0848, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Fischkoff SA, Hersh E, Weber J, Powderly J, Khan K, Pavlick A, Samlowski W, O’Day S, Nichol G, Yellin M. Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7525] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. A. Fischkoff
- Medarex, Inc, Bloomsbury, NJ; Arizona Cancer Ctr, Tucson, AZ; Univ of Southern CA, Los Angeles, CA; Piedmont Oncology Specialists, Charlotte, NC; Community Cancer Care, Indianapolis, IN; New York Univ, New York, NY; Huntsman Cancer Ctr, Salt Lake City, UT; Cancer Institute Medcl Group, Santa Monica, CA
| | - E. Hersh
- Medarex, Inc, Bloomsbury, NJ; Arizona Cancer Ctr, Tucson, AZ; Univ of Southern CA, Los Angeles, CA; Piedmont Oncology Specialists, Charlotte, NC; Community Cancer Care, Indianapolis, IN; New York Univ, New York, NY; Huntsman Cancer Ctr, Salt Lake City, UT; Cancer Institute Medcl Group, Santa Monica, CA
| | - J. Weber
- Medarex, Inc, Bloomsbury, NJ; Arizona Cancer Ctr, Tucson, AZ; Univ of Southern CA, Los Angeles, CA; Piedmont Oncology Specialists, Charlotte, NC; Community Cancer Care, Indianapolis, IN; New York Univ, New York, NY; Huntsman Cancer Ctr, Salt Lake City, UT; Cancer Institute Medcl Group, Santa Monica, CA
| | - J. Powderly
- Medarex, Inc, Bloomsbury, NJ; Arizona Cancer Ctr, Tucson, AZ; Univ of Southern CA, Los Angeles, CA; Piedmont Oncology Specialists, Charlotte, NC; Community Cancer Care, Indianapolis, IN; New York Univ, New York, NY; Huntsman Cancer Ctr, Salt Lake City, UT; Cancer Institute Medcl Group, Santa Monica, CA
| | - K. Khan
- Medarex, Inc, Bloomsbury, NJ; Arizona Cancer Ctr, Tucson, AZ; Univ of Southern CA, Los Angeles, CA; Piedmont Oncology Specialists, Charlotte, NC; Community Cancer Care, Indianapolis, IN; New York Univ, New York, NY; Huntsman Cancer Ctr, Salt Lake City, UT; Cancer Institute Medcl Group, Santa Monica, CA
| | - A. Pavlick
- Medarex, Inc, Bloomsbury, NJ; Arizona Cancer Ctr, Tucson, AZ; Univ of Southern CA, Los Angeles, CA; Piedmont Oncology Specialists, Charlotte, NC; Community Cancer Care, Indianapolis, IN; New York Univ, New York, NY; Huntsman Cancer Ctr, Salt Lake City, UT; Cancer Institute Medcl Group, Santa Monica, CA
| | - W. Samlowski
- Medarex, Inc, Bloomsbury, NJ; Arizona Cancer Ctr, Tucson, AZ; Univ of Southern CA, Los Angeles, CA; Piedmont Oncology Specialists, Charlotte, NC; Community Cancer Care, Indianapolis, IN; New York Univ, New York, NY; Huntsman Cancer Ctr, Salt Lake City, UT; Cancer Institute Medcl Group, Santa Monica, CA
| | - S. O’Day
- Medarex, Inc, Bloomsbury, NJ; Arizona Cancer Ctr, Tucson, AZ; Univ of Southern CA, Los Angeles, CA; Piedmont Oncology Specialists, Charlotte, NC; Community Cancer Care, Indianapolis, IN; New York Univ, New York, NY; Huntsman Cancer Ctr, Salt Lake City, UT; Cancer Institute Medcl Group, Santa Monica, CA
| | - G. Nichol
- Medarex, Inc, Bloomsbury, NJ; Arizona Cancer Ctr, Tucson, AZ; Univ of Southern CA, Los Angeles, CA; Piedmont Oncology Specialists, Charlotte, NC; Community Cancer Care, Indianapolis, IN; New York Univ, New York, NY; Huntsman Cancer Ctr, Salt Lake City, UT; Cancer Institute Medcl Group, Santa Monica, CA
| | - M. Yellin
- Medarex, Inc, Bloomsbury, NJ; Arizona Cancer Ctr, Tucson, AZ; Univ of Southern CA, Los Angeles, CA; Piedmont Oncology Specialists, Charlotte, NC; Community Cancer Care, Indianapolis, IN; New York Univ, New York, NY; Huntsman Cancer Ctr, Salt Lake City, UT; Cancer Institute Medcl Group, Santa Monica, CA
| |
Collapse
|
30
|
Stiff PJ, Shpall EJ, Liu PY, Wilczynski SP, Callander NS, Scudder SA, Jazieh AR, Samlowski W, McCoy J, Alberts DS. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecol Oncol 2004; 94:98-106. [PMID: 15262126 DOI: 10.1016/j.ygyno.2004.02.032] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2003] [Indexed: 01/03/2023]
Abstract
OBJECTIVES To evaluate response rates, progression-free survival (PFS), overall survival (OS), and toxicity of two high-dose chemotherapy regimens with stem cell rescue used to treat patients with recurrent or persistent stage III/IV ovarian cancer, with the goal of taking one forward into a Phase III comparison with conventional therapy. METHODS Patients under 65 with clinically or pathologically persistent disease after initial chemotherapy or those relapsing >6 months after a complete remission (CR) were randomized to CMC carboplatin (1500 mg/m(2)), mitoxantrone (75 mg/m(2)), and cyclophosphamide (120 mg/kg)], or CTC: [cisplatin (165 mg/m(2)), thiotepa (600 mg/m(2)), and cyclophosphamide (5625 mg/m(2))] with stem cell rescue. RESULTS Of 67 randomized, the 32 and 26 eligible in the CMC and CTC arms were matched including age (median 49), maximum tumor diameter, and disease status at transplant. Low-risk disease (maximum diameter disease <or= 0.5 cm and platinum sensitivity) was demonstrated in only approximately one-half of the patients. There were two treatment-related deaths in each arm. The median PFS was 13 and 8 months, respectively, for the CMC and CTC arms. The median OS was 29 and 22 months for the CMC and CTC arms. In a multivariate analysis of PFS, normal CA125 at transplant and CR to primary therapy were significant; for OS, normal CA125 and platinum sensitivity were significant. CONCLUSIONS The CMC regimen was the superior regimen. However, few patients were long-term progression-free survivors. A clinical CR to primary therapy and a normal CA125, seen in a minority of patients, were requirements for a favorable outcome.
Collapse
Affiliation(s)
- Patrick J Stiff
- Loyola University Stritch School of Medicine, Maywood, IL 60153, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Garland L, Rankin C, Scott K, Nagle R, Lobell M, Gandara D, Rivkin S, Samlowski W, Atkins J, Borden E. Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Garland
- Arizona Cancer Center, Tucson, AZ; SWOG Statistical Center, Seattle, WY; UC Davis, Sacramento, CA; Puget Sound Oncology Consortium, Seattle, WA; Univ. of Utah, Salt Lake City, UT; Southeast Cancer Control Consortium, Goldsboro, NC; Cleveland Clinic, Cleveland, OH
| | - C. Rankin
- Arizona Cancer Center, Tucson, AZ; SWOG Statistical Center, Seattle, WY; UC Davis, Sacramento, CA; Puget Sound Oncology Consortium, Seattle, WA; Univ. of Utah, Salt Lake City, UT; Southeast Cancer Control Consortium, Goldsboro, NC; Cleveland Clinic, Cleveland, OH
| | - K. Scott
- Arizona Cancer Center, Tucson, AZ; SWOG Statistical Center, Seattle, WY; UC Davis, Sacramento, CA; Puget Sound Oncology Consortium, Seattle, WA; Univ. of Utah, Salt Lake City, UT; Southeast Cancer Control Consortium, Goldsboro, NC; Cleveland Clinic, Cleveland, OH
| | - R. Nagle
- Arizona Cancer Center, Tucson, AZ; SWOG Statistical Center, Seattle, WY; UC Davis, Sacramento, CA; Puget Sound Oncology Consortium, Seattle, WA; Univ. of Utah, Salt Lake City, UT; Southeast Cancer Control Consortium, Goldsboro, NC; Cleveland Clinic, Cleveland, OH
| | - M. Lobell
- Arizona Cancer Center, Tucson, AZ; SWOG Statistical Center, Seattle, WY; UC Davis, Sacramento, CA; Puget Sound Oncology Consortium, Seattle, WA; Univ. of Utah, Salt Lake City, UT; Southeast Cancer Control Consortium, Goldsboro, NC; Cleveland Clinic, Cleveland, OH
| | - D. Gandara
- Arizona Cancer Center, Tucson, AZ; SWOG Statistical Center, Seattle, WY; UC Davis, Sacramento, CA; Puget Sound Oncology Consortium, Seattle, WA; Univ. of Utah, Salt Lake City, UT; Southeast Cancer Control Consortium, Goldsboro, NC; Cleveland Clinic, Cleveland, OH
| | - S. Rivkin
- Arizona Cancer Center, Tucson, AZ; SWOG Statistical Center, Seattle, WY; UC Davis, Sacramento, CA; Puget Sound Oncology Consortium, Seattle, WA; Univ. of Utah, Salt Lake City, UT; Southeast Cancer Control Consortium, Goldsboro, NC; Cleveland Clinic, Cleveland, OH
| | - W. Samlowski
- Arizona Cancer Center, Tucson, AZ; SWOG Statistical Center, Seattle, WY; UC Davis, Sacramento, CA; Puget Sound Oncology Consortium, Seattle, WA; Univ. of Utah, Salt Lake City, UT; Southeast Cancer Control Consortium, Goldsboro, NC; Cleveland Clinic, Cleveland, OH
| | - J. Atkins
- Arizona Cancer Center, Tucson, AZ; SWOG Statistical Center, Seattle, WY; UC Davis, Sacramento, CA; Puget Sound Oncology Consortium, Seattle, WA; Univ. of Utah, Salt Lake City, UT; Southeast Cancer Control Consortium, Goldsboro, NC; Cleveland Clinic, Cleveland, OH
| | - E. Borden
- Arizona Cancer Center, Tucson, AZ; SWOG Statistical Center, Seattle, WY; UC Davis, Sacramento, CA; Puget Sound Oncology Consortium, Seattle, WA; Univ. of Utah, Salt Lake City, UT; Southeast Cancer Control Consortium, Goldsboro, NC; Cleveland Clinic, Cleveland, OH
| |
Collapse
|
32
|
Hersh EM, Weber J, Powderly J, Yellin M, Kahn K, Pavlick A, Samlowski W, Nichol G, O'Day S. A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7511] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. M. Hersh
- Arizona Cancer Center, Tucson, AZ; USC, Los Angeles, CA; Piedmont Onc. Specialists, Charlotte, NC; Medarex Inc, Bloomsbury, NJ; Community Cancer Care, Indianapolis, IN; New York University, New York, NY; Huntsman Cancer Center, Salt Lake City, UT; Medarex Inc, Bloomsbury, OK; Cancer Inst. Medical Gp., Sant Monica, CA
| | - J. Weber
- Arizona Cancer Center, Tucson, AZ; USC, Los Angeles, CA; Piedmont Onc. Specialists, Charlotte, NC; Medarex Inc, Bloomsbury, NJ; Community Cancer Care, Indianapolis, IN; New York University, New York, NY; Huntsman Cancer Center, Salt Lake City, UT; Medarex Inc, Bloomsbury, OK; Cancer Inst. Medical Gp., Sant Monica, CA
| | - J. Powderly
- Arizona Cancer Center, Tucson, AZ; USC, Los Angeles, CA; Piedmont Onc. Specialists, Charlotte, NC; Medarex Inc, Bloomsbury, NJ; Community Cancer Care, Indianapolis, IN; New York University, New York, NY; Huntsman Cancer Center, Salt Lake City, UT; Medarex Inc, Bloomsbury, OK; Cancer Inst. Medical Gp., Sant Monica, CA
| | - M. Yellin
- Arizona Cancer Center, Tucson, AZ; USC, Los Angeles, CA; Piedmont Onc. Specialists, Charlotte, NC; Medarex Inc, Bloomsbury, NJ; Community Cancer Care, Indianapolis, IN; New York University, New York, NY; Huntsman Cancer Center, Salt Lake City, UT; Medarex Inc, Bloomsbury, OK; Cancer Inst. Medical Gp., Sant Monica, CA
| | - K. Kahn
- Arizona Cancer Center, Tucson, AZ; USC, Los Angeles, CA; Piedmont Onc. Specialists, Charlotte, NC; Medarex Inc, Bloomsbury, NJ; Community Cancer Care, Indianapolis, IN; New York University, New York, NY; Huntsman Cancer Center, Salt Lake City, UT; Medarex Inc, Bloomsbury, OK; Cancer Inst. Medical Gp., Sant Monica, CA
| | - A. Pavlick
- Arizona Cancer Center, Tucson, AZ; USC, Los Angeles, CA; Piedmont Onc. Specialists, Charlotte, NC; Medarex Inc, Bloomsbury, NJ; Community Cancer Care, Indianapolis, IN; New York University, New York, NY; Huntsman Cancer Center, Salt Lake City, UT; Medarex Inc, Bloomsbury, OK; Cancer Inst. Medical Gp., Sant Monica, CA
| | - W. Samlowski
- Arizona Cancer Center, Tucson, AZ; USC, Los Angeles, CA; Piedmont Onc. Specialists, Charlotte, NC; Medarex Inc, Bloomsbury, NJ; Community Cancer Care, Indianapolis, IN; New York University, New York, NY; Huntsman Cancer Center, Salt Lake City, UT; Medarex Inc, Bloomsbury, OK; Cancer Inst. Medical Gp., Sant Monica, CA
| | - G. Nichol
- Arizona Cancer Center, Tucson, AZ; USC, Los Angeles, CA; Piedmont Onc. Specialists, Charlotte, NC; Medarex Inc, Bloomsbury, NJ; Community Cancer Care, Indianapolis, IN; New York University, New York, NY; Huntsman Cancer Center, Salt Lake City, UT; Medarex Inc, Bloomsbury, OK; Cancer Inst. Medical Gp., Sant Monica, CA
| | - S. O'Day
- Arizona Cancer Center, Tucson, AZ; USC, Los Angeles, CA; Piedmont Onc. Specialists, Charlotte, NC; Medarex Inc, Bloomsbury, NJ; Community Cancer Care, Indianapolis, IN; New York University, New York, NY; Huntsman Cancer Center, Salt Lake City, UT; Medarex Inc, Bloomsbury, OK; Cancer Inst. Medical Gp., Sant Monica, CA
| |
Collapse
|
33
|
Worden FP, Moon J, Samlowski W, Clark J, Dakhil SR, Taylor SA, Urba SG, Hussain M. A phase II evaluation of a 3-hour infusion of paclitaxel (P), cisplatin (CDDP) & 5-fluorouracil (5FU) in patients with advanced or recurrent squamous cell carcinoma of the head & neck (SCCHN): A Southwest Oncology Group Study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. P. Worden
- University of Michigan, Ann Arbor, MI; SWOG, Seattle, WA; Huntsman Cancer Institute, Salt Lake City, UT; Loyola Unversity Chicago, Chicago, IL; Wichita CCOP, Wichita, KS; University of Kansas Medical Center, Kansas City, KS
| | - J. Moon
- University of Michigan, Ann Arbor, MI; SWOG, Seattle, WA; Huntsman Cancer Institute, Salt Lake City, UT; Loyola Unversity Chicago, Chicago, IL; Wichita CCOP, Wichita, KS; University of Kansas Medical Center, Kansas City, KS
| | - W. Samlowski
- University of Michigan, Ann Arbor, MI; SWOG, Seattle, WA; Huntsman Cancer Institute, Salt Lake City, UT; Loyola Unversity Chicago, Chicago, IL; Wichita CCOP, Wichita, KS; University of Kansas Medical Center, Kansas City, KS
| | - J. Clark
- University of Michigan, Ann Arbor, MI; SWOG, Seattle, WA; Huntsman Cancer Institute, Salt Lake City, UT; Loyola Unversity Chicago, Chicago, IL; Wichita CCOP, Wichita, KS; University of Kansas Medical Center, Kansas City, KS
| | - S. R. Dakhil
- University of Michigan, Ann Arbor, MI; SWOG, Seattle, WA; Huntsman Cancer Institute, Salt Lake City, UT; Loyola Unversity Chicago, Chicago, IL; Wichita CCOP, Wichita, KS; University of Kansas Medical Center, Kansas City, KS
| | - S. A. Taylor
- University of Michigan, Ann Arbor, MI; SWOG, Seattle, WA; Huntsman Cancer Institute, Salt Lake City, UT; Loyola Unversity Chicago, Chicago, IL; Wichita CCOP, Wichita, KS; University of Kansas Medical Center, Kansas City, KS
| | - S. G. Urba
- University of Michigan, Ann Arbor, MI; SWOG, Seattle, WA; Huntsman Cancer Institute, Salt Lake City, UT; Loyola Unversity Chicago, Chicago, IL; Wichita CCOP, Wichita, KS; University of Kansas Medical Center, Kansas City, KS
| | - M. Hussain
- University of Michigan, Ann Arbor, MI; SWOG, Seattle, WA; Huntsman Cancer Institute, Salt Lake City, UT; Loyola Unversity Chicago, Chicago, IL; Wichita CCOP, Wichita, KS; University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
34
|
Whitehead RP, Unger JM, Flaherty LE, Eckardt JR, Taylor SA, Didolkar MS, Samlowski W, Sondak VK. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study. Invest New Drugs 2002; 19:239-43. [PMID: 11561681 DOI: 10.1023/a:1010624702340] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Malignant melanoma is increasing in frequency at a rapid rate in the United States. Metastatic disease is chemoresistant with DTIC considered the most active single agent. CI-980 is a synthetic mitotic inhibitor that blocks the assembly of tubulin and microtubules. It has shown cytotoxic activity against a broad spectrum of murine and human tumor cell tines. CI-980 can cross the blood brain barrier, is effective when given orally or parenterally, and is active against multidrug resistant cell lines overexpressing P-glycoprotein. In this trial, patients with disseminated melanoma with measurable disease, SWOG performance status of 0-1, no prior chemotherapy or immunotherapy for metastatic disease, and adequate hepatic and renal function, were enrolled. Treatment with CI-980 was given by 72 h continuous i.v. infusion at a dose of 4.5 mg/m2/day, days 1-3 every 21 days. Twenty-four patients were registered on this study with no patients ineligible. They ranged in age from 33-78 with performance status of 0 in 15 patients and 1 in 9 patients. Nineteen patients had visceral disease with 12 having liver involvement. There were no confirmed responses. The overall response rate was 0% (95% CI 0%-14%). The median overall survival is eleven months (95% CI 4-14 months). The most common toxicities were hematologic and consisted of leukopenia/granulocytopenia and anemia, with nausea/vomiting and malaise/fatigue/weakness also frequent. CI-980 administered at this dose and schedule has insufficient activity in the treatment of disseminated malignant melanoma to warrant further investigation.
Collapse
Affiliation(s)
- R P Whitehead
- University of Texas Medical Branch at Galveston, USA
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Meyers FJ, Lew D, Lara PN, Williamson S, Marshall E, Balcerzak SP, Rivkin SE, Samlowski W, Crawford ED. Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124). Invest New Drugs 2001; 16:347-51. [PMID: 10426670 DOI: 10.1023/a:1006128024879] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Up to 30% of patients with advanced germ cell tumors will fail induction chemotherapy or will relapse. New agents with activity in this still potentially curable subgroup of patients are needed. Edatrexate (10-ethyl, 10-deaza-aminopterin) is a methotrexate analogue that has preclinical and clinical activity in breast, lung, and head and neck cancers, as well as in non-Hodgkin's lymphomas. A phase II trial of edatrexate in relapsed or refractory malignant germ cell tumors was conducted by the Southwest Oncology Group (SWOG). Twenty-five patients were enrolled in the trial. Edatrexate was administered intravenously at a dose of 80 mg/m2 weekly for four weeks followed by a one-week rest period. The treatment course was repeated every five weeks. Among the 23 patients evaluable for response, there were no objective responses with all patients developing progressive disease. Thirteen patients (56%) developed Grade 3-4 toxicities, predominantly stomatitis and malaise/fatigue/lethargy. One patient developed Grade 4 anemia while another developed grade 4 anemia and thrombocytopenia. No patients discontinued treatment due to toxicity nor were there any toxic deaths. Edatrexate administered in this dose and schedule has no antitumor activity and has substantial toxicity in patients with relapsed or refractory germ cell tumors.
Collapse
Affiliation(s)
- F J Meyers
- University of California Davis Cancer Center, Sacramento, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1998; 16:890-6. [PMID: 9508170 DOI: 10.1200/jco.1998.16.3.890] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE We evaluated the vincristine, doxorubicin, and dexamethasone (VAD) regimen alone or with chemosensitizers for remission induction and interferon (IFN) versus IFN plus prednisone (IFN/P) for remission maintenance in previously untreated multiple myeloma. PATIENTS AND METHODS Two hundred thirty-three patients were registered for remission-induction therapy with VAD or VAD plus the chemosensitizers verapamil and quinine. Patients who achieved remission were randomized to maintenance therapy with IFNalpha 3 MU in the evening three times weekly or IFN plus 50 mg of prednisone (IFN/P) on the morning after IFN until relapse. RESULTS Two hundred twenty-nine patients were eligible for induction. Fatal toxicities in nine patients who received VAD plus verapamil and quinine led to closure of this arm after 47 registrations. Subsequently, all patients received VAD induction. Despite the high early mortality rate on VAD plus sensitizers, overall survival by induction arm did not differ for median or 5-year survival with approximately 40% of patients surviving 5 years. Eighty-nine eligible patients who achieved remission were randomized to maintenance. Patients who received IFN/P had improved progression-free survival (median, 19 v9 months for IFN; P = .008). After 48 months, progression-free survival on IFN/P was at the thirtieth percentile, whereas it was below the tenth percentile on IFN alone. Median survival from start of maintenance was long on both arms (57 months for IFN/P v 46 months for IFN; P = .36). CONCLUSION IFN/Pwas more effective than IFN alone. Improved relapse-free survival may be attributable to IFN/P or to the use of prednisone for maintenance. This latter alternative is currently being studied.
Collapse
Affiliation(s)
- S E Salmon
- University of Arizona Cancer Center, Tucson, USA
| | | | | | | | | | | | | |
Collapse
|
37
|
Meyskens FL, Kopecky KJ, Appelbaum FR, Balcerzak SP, Samlowski W, Hynes H. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leuk Res 1995; 19:605-12. [PMID: 7564470 DOI: 10.1016/0145-2126(95)00032-j] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
A national cooperative group trial was conducted in 153 patients with chronic myelogenous leukemia (CML) in chronic phase treated with oral pulse busulfan to determine if oral vitamin A can increase the time to blast crisis and enhance survival of patients. Patients diagnosed within 1 year and in the chronic phase of CML were randomized to receive oral pulse busulfan or the alkylator plus continuous oral vitamin A. Distributions of clinical progression and overall survival were estimated using the method of Kaplan and Meier. Associations of these endpoints with treatment and other patient characteristics were analyzed using the proportional hazards regression method of Cox. Both regimes were well tolerated. Patients in the busulfan plus vitamin A arm had somewhat longer durations of clinical progression-free survival (median 46 months) and overall survival (51 months) compared to those in the busulfan arm (medians 38 and 44 months). However, the differences were not statistically significant (one-tailed P = 0.11 for clinical progression-free survival, 0.081 for survival). After adjustment for significant factors identified in an additional exploratory multivariate analysis, risk of clinical progression or death was 53% (P = 0.022) greater and risk of death 60% (P = 0.014) greater among busulfan patients. Given the relatively large though non-significant difference between treatment arms, the limited statistical power of the study, and the likelihood that oral vitamin A may not be the most effective means of delivering retinoid therapy, we conclude that further investigation of retinoids in chronic phase CML is warranted.
Collapse
|
38
|
Meyskens FL, Liu PY, Tuthill RJ, Sondak VK, Fletcher WS, Jewell WR, Samlowski W, Balcerzak SP, Rector DJ, Noyes RD. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 1994; 12:2060-5. [PMID: 7931474 DOI: 10.1200/jco.1994.12.10.2060] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
PURPOSE A national cooperative group trial was conducted in patients with early-stage cutaneous malignant melanoma to determine if oral vitamin A can increase disease-free survival or survival. PATIENTS AND METHODS Two hundred forty-eight patients with completely resected melanoma of Breslow's thickness greater than 0.75 mm and clinically negative lymph nodes were randomized to oral vitamin A (100,000 IU/d) for 18 months or to observation. Patients were stratified by Breslow's thickness of primary lesion (0.76 to 1.50 mm, 1.51 to 3.00 mm, or > 3.00 mm), sex, and type of therapy (excision, excision plus node dissection, excision plus perfusion, or excision plus both). The median duration of follow-up observation of living patients is greater than 8 years. The relative risk (RR) in disease-free survival and overall survival in the treatment compared with the observation group was calculated using Cox proportional hazards models. RESULTS Overall, there was no difference in disease-free survival or overall survival between the two groups. Examination of treatment by stratification interactions and subset analysis did not show any treatment-effect differences based on sex or type of therapy. There was also no difference between groups in disease-free survival based on Breslow's thickness of the primary lesion. Overall, 12% of patients who received vitamin A experienced grade 3 or 4 toxicities. CONCLUSION Based on the lack of overall survival benefit, further evaluation of vitamin A as adjuvant therapy for melanoma does not appear warranted.
Collapse
|
39
|
Wizenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J 1982; 103:468-73. [PMID: 6278906 DOI: 10.1016/0002-8703(82)90331-3] [Citation(s) in RCA: 102] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Ten consecutive patients with tissue-proven amyloidosis, seven of whom presented with congestive heart failure, were found to exhibit intense diffuse uptake of technetium-99m-pyrophosphate (Tc-99m-PYP) on cardiac radionuclide imaging. The patients exhibited echocardiographic and systolic time interval abnormalities suggesting combined restrictive and congestive cardiomyopathic changes. On M-mode echocardiograms, there was symmetrically increased thickness of the interventricular septum and left ventricular (LV) posterior wall in diastole (10 of 10), decreased fractional shortening of the LV minor axis diameter in systole (eight of nine), and decreased percent thickening of the LV minor axis diameter in systole (eight of nine) and LV posterior wall (10 of 10) in systole. Three patients demonstrated enlarged LV end-diastolic diameter. All 10 patients had abnormal PEP/LVET and eight had shortened LVETI. When combined with noninvasive tests of LV performance, positive myocardial pyrophosphate (PYP) scanning provides a new and useful adjunct in the diagnosis of amyloid heart disease.
Collapse
|